FDA Greenlights Trial for Novel Regenerative Hair Loss Therapy

IRVINE, Calif. – March 24, 2026 – A new chapter in the fight against hair loss may be dawning as the U.S. Food and Drug Administration (FDA) has given the green light for human trials of a novel regenerative therapy. Xtressé™, a hair health company founded by dermatologists and scientists, announced today it has received FDA acceptance for its Investigational New Drug (IND) application for Xvie, a first-of-its-kind injectable treatment for androgenetic alopecia, the most common form of hair loss.

The decision allows Xtressé™ to proceed with a combined Phase I/II clinical trial, a critical step to evaluate the safety and efficacy of Xvie. This marks a significant milestone, not just for the company, but for the entire field of hair restoration, potentially ushering in a new category of treatment that moves beyond the decades-old pharmaceuticals that currently dominate the market.

The Dawn of a Regenerative Approach

For millions of men and women experiencing hair thinning, the options have long been limited. The two most common FDA-approved drugs, minoxidil and finasteride, are decades old and primarily work to slow loss or stimulate existing follicles rather than regenerating the underlying cellular environment. Xvie proposes a fundamentally different approach.

"Hair loss is a biologically complex condition affecting over 80 million people nationwide, and meaningful treatment requires addressing more than a single pathway," said Dr. Matt Leavitt, DO, Co-Founder of Xtressé™, in a statement. "We founded Xtressé™ to advance regenerative approaches that target the underlying biology of hair loss and support follicle function."

At the heart of Xvie is a concentrate derived from amniotic fluid, a substance rich in biological signals. The therapy is designed to be a "multi-signal concentrate" containing a potent mix of growth factors, peptide molecules, natural hyaluronic acid, and, most notably, extracellular vesicles (EVs). These tiny vesicles act as messengers between cells, carrying proteins and genetic information that can influence the behavior of surrounding tissue.

"Amniotic fluid is one of the most biologically complex substances in the human body, containing over 700 unique growth factors and proteins and it has been clinically underutilized as a therapeutic source," explained Trillitye Paullin, PhD, Xtressé's Chief Scientific Officer. Dr. Paullin highlighted the novelty of their method: "By isolating and concentrating the extracellular vesicles from decellularized human amniotic fluid, we've created something that, to our knowledge, has never entered the FDA clinical trial pathway for hair restoration before."

The company emphasizes that Xvie is 100% natural, not artificially cultured or expanded in a lab, and contains no added preservatives or antibiotics, a profile designed to appeal to patients seeking more naturalistic, biologically-based solutions.

Navigating a Crowded and Cautious Market

While the IND acceptance is a moment of promise, Xvie is entering a complex and competitive landscape. The global hair loss treatment market is valued in the tens of billions of dollars, fueled by a significant unmet need. However, the path from an early-phase trial to an approved, marketable drug is long and fraught with risk. Historically, the probability of a drug successfully navigating all clinical phases to final approval is less than 15%.

Xvie's FDA-monitored trial, however, sets it apart from many other "regenerative" treatments currently on the market, such as Platelet-Rich Plasma (PRP). While popular, PRP therapies are often administered off-label, lack standardization in their preparation and application, and have produced variable results in clinical studies. By pursuing a formal IND pathway, Xtressé™ is subjecting Xvie to the rigorous scientific and safety scrutiny required by the FDA, which could ultimately lead to a more reliable and reproducible treatment if successful.

"Preclinical research on extracellular vesicle-based therapies has shown real promise on the follicular pathways that matter," Dr. Paullin noted, referencing a body of scientific literature that supports the potential for EVs to encourage hair follicles to shift from a resting phase (telogen) to a growth phase (anagen).

The pipeline for new alopecia treatments is active, with dozens of companies exploring novel mechanisms, from androgen receptor antagonists to Wnt signaling pathway activators. Success for Xvie will depend not only on demonstrating clear safety and efficacy in its upcoming trials but also on proving its superiority or providing a valuable alternative to both existing treatments and other emerging competitors.

A New Hope for Millions

For the more than 80 million Americans dealing with androgenetic alopecia, the news of a potential new regenerative therapy is more than just a scientific curiosity. Hair loss is frequently described by medical professionals and patients alike as an emotionally taxing condition that can severely impact self-esteem, confidence, and overall quality of life. Frustration with the limited effectiveness and potential side effects of current treatments is a common theme in online patient forums and support groups.

The prospect of a treatment that works by supporting the body's own regenerative capabilities, rather than simply managing symptoms, resonates deeply with this community. Xvie's approach, which aims to create a healthier "signaling environment" for follicles, represents the kind of fundamental innovation many have been waiting for.

While the injectable formulation of Xvie proceeds through the lengthy clinical trial process and is not yet available to the public, Xtressé™ currently offers a topical formulation, Xvie XO Concentrate, for in-office administration by qualified medical providers. This is part of the company's broader strategy to offer a comprehensive system that includes at-home products like their Hair Growth Gummies and FR Concentrate Serum, tackling hair health from multiple angles.

The FDA's acceptance of the IND application for the injectable Xvie does not guarantee its future success, but it validates the preclinical science and clears the path for the necessary human studies to begin. For the millions watching and waiting, this first step is a pivotal moment, representing a tangible move toward a new generation of solutions for one of the most common and challenging cosmetic and medical conditions.